title: [Antidiabetic therapy--a new possibility in the complex therapy of cancer?].
abstract: Nowadays the lack of exercise and improper eating habits are main characteristics of modern life style. This favors not only formation of type 2 diabetes or cardiovascular diseases, but also increaseas the incidence and prevalence of malignant tumors. Today there are many epidemiologic trials that demonstrate the connection between type 2 diabetes and formation of several malignomas. Its cause should be searched in common paths of pathologic processes. One of this is the birth of hyperinsulinsulinemia, which accompanies insulin resistance. Hyperinsulinemia of the host leads to increased glucose uptake in the highly insuline sensitive tumor cells which supports tumor growth. This makes type 2 diabetes a metabolic state favoring tumor formation, suggesting a potential application of oral insulin sensitizers in cancer therapy. Currently several international trials are testing the anti-tumor activity of metformin and thiazolidinedions (TZD). Besides this, encouraging results were obtained with the use of anti-IGFR antibodies in the treatment of tumors. A common therapy of diabetes and tumor may lead to new possibilities in the treatment of malignant tumor diseases. By doing this we could be able to weaken the tumor and strengthen the body, enabling it to fight against cancer. Bánhegyi RJ, Rus-Gal PO, Nagy AK, Martyin T, Varga R, Pikó B. Correlation between type 2 diabetes and malignant tumors - new possibilities in the complex therapy of cancers?
authors.affiliation: Békés Megyei Képviselőtestület Pándy Kálmán Kórháza Megyei Onkológiai Központ 5700 Gyula Semmelweis u. 1. bert@gmail.com
authors.forename: Róbert János
authors.initials: RJ
authors.lastname: Bánhegyi
authors.forename: Paul Ovidiu
authors.initials: PO
authors.lastname: Rus-Gal
authors.forename: Agnes Krisztina
authors.initials: AK
authors.lastname: Nagy
authors.forename: Tibor
authors.initials: T
authors.lastname: Martyin
authors.forename: Róbert
authors.initials: R
authors.lastname: Wágner
authors.forename: Richárd
authors.initials: R
authors.lastname: Varga
authors.forename: Béla
authors.initials: B
authors.lastname: Pikó
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000209:etiology / Q000378:metabolism*; D005247:Feeding Behavior; D006801:Humans; D006946:Hyperinsulinism / Q000097:blood / Q000150:complications / Q000453:epidemiology / Q000378:metabolism*; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007333:Insulin Resistance; D008687:Metformin / Q000494:pharmacology; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000378:metabolism* / Q000517:prevention & control; D017451:Receptors, Somatomedin / Q000276:immunology; D012307:Risk Factors; D040242:Risk Reduction Behavior; D057185:Sedentary Behavior; D045162:Thiazolidinediones / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007004:Hypoglycemic Agents; D017451:Receptors, Somatomedin; D045162:Thiazolidinediones; D008687:Metformin